Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Optimistic Scenario:

Berlin should sell the company in its entirely to maximize shareholder value instead of continuing to dilute and kick the can down the road that only benefits management while value erodes further. ADXS has approximately $30 million in cash left. The company valuation is now around $20 million. I think Berlin could get a buyer to purchase ADXS for $40 million (share price of $0.50 to $0.60). The buyer would get $30 million cash to pocket and be paying $10 million for the IP and shareholders would get a double from here. That's the most optimistic scenario at this stage, because if the reverse split and massive dilution goes through, it's more of the same...shafting shareholders while management protects their paychecks.